Logiscreen

Lexaria Bioscience Corp

$0.65
Market Cap 16.09M
ROE -190.1%
Gross Margin 100.0%
Debt/Equity 0.0
Current Ratio 26.9
Revenue QoQ -88.5%
EPS QoQ -0.6%
F-Score 5

About

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-1.69
vs median 34.32
P/B
2.44
vs median 2.21
ROE
-1.90
vs median 0.09

Decent quality with acceptable fundamentals

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics